Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (201-210 of 584) with videos related to

Pageof 59
Sort By:
Leukemia Research|February 6, 2009
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosisArturo Vega-Ruiz, Jorge E Cortes, Matjaz Sever, et al.
Archives of General Psychiatry|April 16, 2003
Guideline recommendations for treatment of schizophrenia: the impact of managed careBarbara Dickey, Sharon-Lise T Normand, Richard C Hermann, et al.
Journal of Neuro-Oncology|February 11, 2015
Myelopathy following intrathecal chemotherapy in adults: a single institution experienceDavid Cachia, Carlos Kamiya-Matsuoka, Chelsea C Pinnix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistanceWenyong W Zhang, Jorge E Cortes, Hui Yao, et al.
Blood Cancer Journal|March 24, 2026
Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysisMarisol Miranda-Galvis, Joshua Wilson, Yazmin Reategui-Almonacid, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
AMB : Revista Da Associacao Medica Brasileira|March 1, 1984
[The determination of blood pressure in routine medical practice]I Lessa, E Cortes, G Menezes, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patientsMikako Warren, Rajyalakshmi Luthra, C Cameron Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Elias Jabbour, Hagop M Kantarjian, Susan O'Brien, et al.
Pageof 59

Showing results (201-210 of 584) with videos related to

Sort By:
Pageof 59
Leukemia Research|February 6, 2009
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosisArturo Vega-Ruiz, Jorge E Cortes, Matjaz Sever, et al.
Archives of General Psychiatry|April 16, 2003
Guideline recommendations for treatment of schizophrenia: the impact of managed careBarbara Dickey, Sharon-Lise T Normand, Richard C Hermann, et al.
Journal of Neuro-Oncology|February 11, 2015
Myelopathy following intrathecal chemotherapy in adults: a single institution experienceDavid Cachia, Carlos Kamiya-Matsuoka, Chelsea C Pinnix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistanceWenyong W Zhang, Jorge E Cortes, Hui Yao, et al.
Blood Cancer Journal|March 24, 2026
Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysisMarisol Miranda-Galvis, Joshua Wilson, Yazmin Reategui-Almonacid, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
AMB : Revista Da Associacao Medica Brasileira|March 1, 1984
[The determination of blood pressure in routine medical practice]I Lessa, E Cortes, G Menezes, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2012
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patientsMikako Warren, Rajyalakshmi Luthra, C Cameron Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Elias Jabbour, Hagop M Kantarjian, Susan O'Brien, et al.
Pageof 59